BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX), a leading developer of DNA vaccines and therapies for HIV infection, announced today that its collaborators from the University of Pennsylvania presented data showing enhanced magnitude and quality of immune responses induced by VGX’s DNA vaccines with electroporation delivery compared to those induced by the recombinant Adenovirus Serotype 5 (Ad5) vector. The data was presented at the recent 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) held in Montreal, Canada.
